Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 11:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,649 matching trials from the live ClinicalTrials.gov search.
Terminated Phase 3 Interventional Results available

A Study of LY2140023 in Patients With Schizophrenia

NCT01307800
Conditions
Schizophrenia
Interventions
LY2140023, Placebo
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Wichita, Kansas
Conditions
Schizophrenia
Interventions
Placebo, Valbenazine
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
50
States / cities
Phoenix, Arizona • Rogers, Arkansas • Anaheim, California + 39 more
Conditions
Schizophrenia
Interventions
Brenipatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
32
States / cities
Little Rock, Arkansas • Bellflower, California • Garden Grove, California + 28 more
Completed Not applicable Interventional

L-carnosine for Schizophrenia

NCT00177177
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
L-carnosine (dietary supplement)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
4
States / cities
Bridgeville, Pennsylvania • DuBois, Pennsylvania • McKeesport, Pennsylvania + 1 more
Conditions
Schizophrenia
Interventions
active H-coil delivered rTMS
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Houston, Texas
Conditions
Type 2 Diabetes Mellitus, Serious Mental Illness, Schizophrenia, Major Depression, Bipolar Disorder
Interventions
Lifestyle MIND
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Psychoeducation
Behavioral
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Belmont, Massachusetts • Boston, Massachusetts
Withdrawn Not applicable Interventional

Home-based Exercise for SMI

NCT06078293
Conditions
Serious Mental Illness
Interventions
Home-based Exercise Program
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Providence, Rhode Island
Completed No phase listed Observational Accepts healthy volunteers

Bipolar and Schizophrenia Consortium for Parsing Intermediate Phenotypes

NCT00666432
Conditions
Schizophrenia, Bipolar
Interventions
This is an observational study model that is family based
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
15 Years and older
Enrollment
3,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2019
U.S. locations
6
States / cities
Hartford, Connecticut • Chicago, Illinois • Baltimore, Maryland + 2 more
Conditions
Schizophrenia, Insulin Resistance
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Schizophrenia
Interventions
SKL15508, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Glendale, California
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Single Dose Intranasal Insulin On Cognitive Function

NCT00646581
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Placebo, Insulin (Humulin)
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Schizophrenia
Interventions
Asenapine, Placebo Asenapine, Olanzapine, Placebo Olanzapine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Austin, Texas
Conditions
Schizophrenia
Interventions
Olanzapine, Perphenazine, Aripiprazole, Metformin, Simvastatin, Benztropine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
13
States / cities
Colton, California • Palo Alto, California • New Haven, Connecticut + 10 more
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin tartrate (ACP-103), Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
40 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
36
States / cities
Gilbert, Arizona • Phoenix, Arizona • Berkeley, California + 33 more
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder
Interventions
clozapine, risperidone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Hartford, Connecticut • Athens, Georgia • Chicago, Illinois + 2 more
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Team-Based Quality Improvement Intervention, Opinion Leader Intervention, Team Based Quality Improvement
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Fayetteville, Arkansas • No. Little Rock, Arkansas • Dayton, Ohio + 1 more
Conditions
Schizophrenia
Interventions
D-cycloserine, Glycine, Clozapine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Schizophrenia
Interventions
Risperidone, RBP-7000
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Little Rock, Alaska • Long Beach, California
Completed Phase 2 Interventional Results available

A Study of ALKS 3831 in Adults With Schizophrenia

NCT01903837
Conditions
Schizophrenia
Interventions
Samidorphan (Low Dose), Samidorphan (Medium Dose), Samidorphan (High Dose), Placebo, Olanzapine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
50
States / cities
Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 43 more
Conditions
Tobacco Use, Tobacco Smoking, Tobacco Use Cessation, Tobacco Use Disorder, Schizophrenia, Schizoaffective Disorder
Interventions
Persistence Targeted Smoking Cessation in SMI (PTSC-S), Nicotine patch
Behavioral · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Schizophrenia
Interventions
Placebo, RO4917838, Antipshychotics (Standard of Care)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
27
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 23 more
Conditions
Schizophrenia
Interventions
ALKS 9072, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
26
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Cerritos, California + 20 more
Completed Not applicable Interventional Results available

Brain Stimulation and Cognitive Training - Efficacy

NCT05111548
Conditions
Schizophrenia, Schizo Affective Disorder, Bipolar Disorder
Interventions
tDCS (Active), BrainHQ, tDCS (Inactive)
Device · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan